Insider · CIK 0001595930
Jeffrey Arvin Fink
Files at LPCN (Lipocine Inc.). First filing -, latest -.
Jeffrey Arvin Fink files SEC Form 4 as director at LPCN (Lipocine Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeffrey Arvin Fink has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | LPCN Lipocine Inc. | AGrant or award Common Stock (Right to Buy)derivative | +1,764 | $3.20 | $5,645 | 11,526 | Jun 5, 2025 |
Questions about Jeffrey Arvin Fink
Answered from the filings on this page, as of the latest one.
Is Jeffrey Arvin Fink buying or selling?
Jeffrey Arvin Fink has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeffrey Arvin Fink's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey Arvin Fink has 0.
Where does Jeffrey Arvin Fink file Form 4?
Jeffrey Arvin Fink has filed Form 4 at LPCN (Lipocine Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.